Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2014

01-03-2014 | Original Paper

Prostate-specific membrane antigen as a marker of pancreatic cancer cells

Authors: He Ren, Huan Zhang, Xiuchao Wang, Junxiu Liu, Zhanna Yuan, Jihui Hao

Published in: Medical Oncology | Issue 3/2014

Login to get access

Abstract

The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef
3.
Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.PubMedCrossRef
4.
Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef
5.
Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977–85.PubMed
6.
Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547–51.PubMed
7.
Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915–8.PubMedCrossRef
8.
Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef
9.
Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471–81.CrossRef
10.
11.
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.PubMedCrossRef
12.
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMed
13.
Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205–11.PubMedCrossRef
14.
McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163–75.CrossRef
15.
Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182–90.PubMedCrossRef
16.
Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.PubMed
17.
18.
Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532–41.PubMedCentralPubMedCrossRef
Metadata
Title
Prostate-specific membrane antigen as a marker of pancreatic cancer cells
Authors
He Ren
Huan Zhang
Xiuchao Wang
Junxiu Liu
Zhanna Yuan
Jihui Hao
Publication date
01-03-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0857-z

Other articles of this Issue 3/2014

Medical Oncology 3/2014 Go to the issue

Letter to the Editor

Haplotype analysis of the C677T and A1298C polymorphisms of MTHFR and susceptibility to chronic myeloid leukemia

Original Paper

Hepato-biliary-enteric stent drainage as palliative treatment for proximal malignant obstructive jaundice

Original Paper

A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach

Original Paper

Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Original Paper

Low serum levels of vitamin D in metastatic cancer patients: a case–control study

Short Communication

Dose adjustment of carboplatin in patients on hemodialysis

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits